logo BDSP

Base documentaire


  1. Fulltext. Benefits of influenza Vaccination for low-intermediate-and high-risk senior citizens.

    Article - En anglais

    Fulltext.

    Background 

    Vaccination rates for healthy senior citizens are lower than those for senior citizens with underlying medical conditions such as chronic heart or lung disease.

    Uncertainty about the benefits of influenza vaccination for healthy senior citizens may contribute to lower rates of utilization in this group.

    Objective 

    To clarify the benefits of influenza vaccination among low-risk senior citizens while concurrently assessing the benefits for intermediate-and high-risk senior citizens.

    Methods 

    All elderly members of a large health maintenance organization were included in each of 6 consecutive study cohorts.

    Subjects were grouped according to risk status : high risk (having heart or lung disease), intermediate risk (having diabetes, renal disease, stroke and/or dementia, or rheumatologic disease), and low risk.

    Outcomes were compared between vaccinated and unvaccinated subjects after controlling for baseline demographic and health characteristics.

    Results 

    There were more than 20 000 subjects in each of the 6 cohorts who provided 147 551 person-periods of observation.

    The pooled vaccination rate was 60%. There were 101619 person-periods of observation for low-risk subjects, 15 482 for intermediate-risk, and 30 450 for high-risk subjects.

    Vaccination over the 6 seasons was associated with an overall reduction of 39% for pneumonia hospitalizations (P<. 001), a 32% decrease in hospitalizations for all respiratory conditions (P<. (...)

    Mots-clés Pascal : Grippe, Virose, Infection, Vaccination, Vieillard, Homme, Etude cohorte, Profit, Risque élevé, Analyse statistique, Etats Unis, Amérique du Nord, Amérique, Immunoprophylaxie

    Mots-clés Pascal anglais : Influenza, Viral disease, Infection, Vaccination, Elderly, Human, Cohort study, Benefit, High risk, Statistical analysis, United States, North America, America, Immunoprophylaxis

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0431710

    Code Inist : 002B05A02. Création : 25/01/1999.